Hologic (NASDAQ:HOLX) had its price objective lowered by Jefferies Group from $26.00 to $24.00 in a report released on Tuesday, Analyst Ratings Network.com reports. Jefferies Group currently has a buy rating on the stock.
Shares of Hologic (NASDAQ:HOLX) traded down 1.46% on Tuesday, hitting $20.21. The stock had a trading volume of 984,734 shares. Hologic has a 52-week low of $18.46 and a 52-week high of $23.96. The stock has a 50-day moving average of $21.71 and a 200-day moving average of $21.21. The company’s market cap is $5.466 billion. Hologic also saw some unusual options trading on Tuesday. Stock traders purchased 6,011 put options on the stock. This is an increase of approximately 698% compared to the typical volume of 753 put options.
Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 11th. The company reported $0.39 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.37 by $0.02. The company had revenue of $622.10 million for the quarter, compared to the consensus estimate of $624.40 million. During the same quarter in the prior year, the company posted $0.37 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. Analysts expect that Hologic will post $1.44 EPS for the current fiscal year.
In other Hologic news, CFO Glenn P. Muir sold 140,000 shares of the company’s stock on the open market in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $22.32, for a total transaction of $3,124,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Several other analysts have also recently commented on the stock. Analysts at ISI Group cut their price target on shares of Hologic from $26.00 to $25.00 in a research note to investors on Tuesday. They now have a strong-buy rating on the stock. Separately, analysts at Cantor Fitzgerald cut their price target on shares of Hologic from $21.00 to $19.00 in a research note to investors on Tuesday. They now have a hold rating on the stock. Finally, analysts at Citigroup Inc. reiterated a neutral rating on shares of Hologic in a research note to investors on Tuesday. They now have a $22.00 price target on the stock, down previously from $24.00. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $22.00.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.